Oncopeptides has announced that the first patient has been enrolled in the phase 2 PORT study.
The study, which is expected to be fully recruited in December 2020, is an open-label, randomized, cross-over study which compares safety, tolerability and efficacy of peripheral or central intravenous administration of melflufen in combination with dexamethasone in patients with relapsed refractory multiple myeloma, RRMM.
Up to 25 RRMM patients who have received at least two previous lines of therapy will be enrolled.
“Patients who receive anti-cancer treatment often get an implanted port, a type of central venous catheter placed under the skin, to limit the number of needle sticks, facilitate intravenous administration and enhance convenience. The PORT study may provide an additional option in the way melflufen is delivered,” says Klaas Bakker, CMO of Oncopeptides. “Broadening the mode of administration would allow physicians to choose the option that is preferable for their patients.”
Photo of Klaas Bakker: Oncopeptides
